1
00:00:02,200 --> 00:00:05,655
Thymosin alpha one opens our immune
defense and inflammation

2
00:00:05,680 --> 00:00:06,540
collection.

3
00:00:07,220 --> 00:00:09,980
Immune health depends on coordinated
responses.

4
00:00:10,840 --> 00:00:14,875
In nineteen seventy-seven, Allan Goldstein
and colleagues reported

5
00:00:14,900 --> 00:00:18,735
the isolation and sequence of this
twenty-eight-amino-acid peptide

6
00:00:18,760 --> 00:00:20,100
from calf thymus.

7
00:00:20,660 --> 00:00:24,640
Its synthetic counterpart has the same
amino acid sequence.

8
00:00:25,360 --> 00:00:28,700
Laboratory studies examine how it
influences dendritic cells,

9
00:00:29,120 --> 00:00:31,935
which help present information to T cells.

10
00:00:31,960 --> 00:00:36,135
This connects rapid innate defenses with
targeted adaptive

11
00:00:36,160 --> 00:00:36,980
responses.

12
00:00:38,020 --> 00:00:41,335
Changes in an immune marker are not
automatically clinical

13
00:00:41,360 --> 00:00:41,800
benefits.

14
00:00:42,540 --> 00:00:45,895
That distinction matters in sepsis, where
a dangerous response

15
00:00:45,920 --> 00:00:48,220
to infection can damage organs.

16
00:00:49,600 --> 00:00:53,155
The TESTS trial enrolled eleven hundred
six adults at

17
00:00:53,180 --> 00:00:54,720
twenty-two centers in China.

18
00:00:55,600 --> 00:01:00,435
Participants received thymosin alpha one
or placebo alongside

19
00:01:00,460 --> 00:01:01,635
standard care.

20
00:01:01,660 --> 00:01:05,335
Among the one thousand eighty-nine
participants analyzed,

21
00:01:05,360 --> 00:01:09,535
twenty-eight-day mortality was
twenty-three point four percent

22
00:01:09,560 --> 00:01:13,155
with the peptide and twenty-four point one
percent with

23
00:01:13,180 --> 00:01:13,680
placebo.

24
00:01:14,780 --> 00:01:18,220
The corrected report found no clear
mortality benefit.

25
00:01:19,020 --> 00:01:22,960
Its confidence interval included possible
benefit and harm.

26
00:01:23,620 --> 00:01:27,415
These findings describe a specific
treatment strategy in adults

27
00:01:27,440 --> 00:01:28,440
with sepsis.

28
00:01:29,080 --> 00:01:31,640
They do not settle every question about
thymosin alpha

29
00:01:32,500 --> 00:01:37,520
one or demonstrate an immune-boosting
benefit in healthy people.

30
00:01:38,480 --> 00:01:42,695
Similar reported safety outcomes do not
establish long-term

31
00:01:42,720 --> 00:01:43,400
safety.

32
00:01:43,980 --> 00:01:46,995
In the United States, it is not an
F-D-A-approved

33
00:01:47,020 --> 00:01:47,580
medicine.

34
00:01:48,460 --> 00:01:52,095
Connect immune biology to a defined
disease, a measured

35
00:01:52,120 --> 00:01:55,380
outcome, and the strength of the human
evidence.

36
00:01:56,180 --> 00:01:57,455
World Peptide Foundation.

37
00:01:57,480 --> 00:02:00,395
Peptides in 2.

38
00:02:00,420 --> 00:02:01,760
Every experience matters.